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Available online 12 April 2017Despite being overexpressed in different tumor entities, RIO kinases are hardly characterized inmammalian cells.
We investigated the role of these atypical kinases in different cancer cells. Using isogenic colon-, breast- and lung
cancer cell lines, we demonstrate that knockdown of RIOK1, but not of RIOK2 or RIOK3, strongly impairs prolif-
eration and invasiveness in conventional and 3D culture systems. Interestingly, these effects were mainly ob-
served in RASmutant cancer cells. In contrast, growth of RAS wildtype Caco-2 and Bcr-Abl-driven K562 cells is
not affected by RIOK1 knockdown, suggesting a speciﬁc requirement for RIOK1 in the context of oncogenic
RAS signaling. Furthermore, we show that RIOK1 activates NF-κB signaling and promotes cell cycle progression.
Using proteomics, we identiﬁed the pro-invasive proteins Metadherin and Stathmin1 to be regulated by RIOK1.
Additionally, we demonstrate that RIOK1 promotes lung colonization in vivo and that RIOK1 is overexpressed in
different subtypes of human lung- and breast cancer. Altogether, our data suggest RIOK1 as a potential therapeu-
tic target, especially in RAS-driven cancers.
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Kinases represent ideal targets for rational combination therapies
due to their well-established druggability (Davis et al., 2011; Manning
et al., 2002). Many tumors, however, still express undruggable
oncoproteins and therefore the design of rational combination therapies
that target several of their effector pathways or create a synthetic lethal
condition in oncoprotein expressing cells has become a major topic in
oncology (Horn et al., 2016).icine and Cell Research, Stefan-
r).
. This is an open access article underIndeed,mutations in the three hitherto undruggable RASproteins (K-
Ras, N-Ras, H-Ras) represent major drivers in cancer, leading to chronic
activation of the PI3K-AKT and RAF-MEK-ERK pathways (Cox et al.,
2014; Eser et al., 2013; Hayes et al., 2016; Rajalingamet al., 2007). There-
fore, the ﬁeld has focused on efﬁcient targeting of the kinases in the RAS
effector pathways, in particular the MEK-ERK kinases and the PI3K-PDK
axis (Eser et al., 2013; Hayes et al., 2016). Other effectors such as the JAK-
STAT and NF-κB signaling pathways are also chronically activated in RAS
mutant cells (Nicolae et al., 2016; Yang et al., 2015). Rational drug com-
binations that exploit cancer speciﬁc vulnerabilities while avoiding toxic
side-effects, however, will require an in-depth knowledge about the
complexities of these pathways, in particular their intricate regulation
by protein complex formation, feedback- and robustness phenomena
(Fritsche-Guenther et al., 2011; Samatar & Poulikakos, 2014). A major
step in this direction is therefore the identiﬁcation of novel druggablethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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targetable nodes in oncoprotein networks, for example by creating syn-
thetic lethal constellations (Downward, 2015). Surprisingly, themajority
of to date investigated kinases represents b10% of the kinome andhas al-
ready been known prior to the human genome project (Edwards et al.,
2011). Thus, there is a long tail of under-researched and ill-deﬁned ki-
nases that might represent promising drug targets, either on their own
or in combinatorial settings.
Previously, we have reported an RNA interference screen for kinases
modulating aberrant signaling by the G13E mutant of the LET-60 RAS
orthologue in Caenorhabditis elegans (Weinberg et al., 2014). Thismuta-
tion affects the evolutionary conserved glycine residue that is frequently
mutated in the RAS proteins in human tumors (Cox et al., 2014). In this
screen, knockdown of RIOK1, a member of the RIO protein kinase fam-
ily, led to a strong suppression of the well-characterized RASG13E driven
multi-vulva phenotype.
RIO kinases represent a family of ancient atypical protein kinases
found in all kingdoms of life. Compared to typical eukaryotic protein ki-
nases, they lack substrate recognition sites and conserved activation loop
motifs, although they hydrolyze ATP in vitro (Angermayr & Bandlow,
2002; Laronde-Leblanc et al., 2005; LaRonde-LeBlanc & Wlodawer,
2005a, b). The Saccharomyces cerevisiae orthologues, Rio1 and Rio2,
were originally identiﬁed and characterized as essential genes for cell
cycle progression and ribosomal biogenesis (Angermayr & Bandlow,
2002; LaRonde-LeBlanc & Wlodawer, 2005b; Vanrobays et al., 2003).
Their abundance and kinase activity are critical for maturation of the
40S small ribosomal subunit (Ferreira-Cerca et al., 2014; Ferreira-Cerca
et al., 2012). RIO proteins deﬁcient for ATP-binding or for catalytic activ-
ity impair ribosomal biogenesis and delay cell cycle exit (Baumas et al.,
2012; Ferreira-Cerca et al., 2014; LaRonde-LeBlanc & Wlodawer, 2005a;
Widmann et al., 2012). Several studies also conﬁrmed these functions
in mammalian cells for RIOK1, RIOK2 and, for the metazoan speciﬁc
third member of the family, RIOK3 (Baumas et al., 2012; Widmann
et al., 2012; Zemp et al., 2009). However, only a few substrates for RIO ki-
nases have been identiﬁed so far (Iacovella et al., 2015; Takashima et al.,
2015) and besides their involvement in ribosomal biogenesis, additional
and potentially isoform-speciﬁc functions remain to be characterized.
Importantly, RIO kinases are overexpressed in various cancer types,
although the functional signiﬁcance remains unknown. RIOK1 overex-
pression has been observed in colorectal cancer (Line et al., 2002) and
in non-small cell lung cancer (NSCLC). In the latter, RIOK1 was co-
overexpressed with the growth promoting proteins MAPJD (Myc-
associated protein with JmjC domain) and PRMT5 (protein arginine
methyl transferase 5) (Guderian et al., 2011; Suzuki et al., 2007).
RIOK2 is overexpressed in glioblastoma (Read et al., 2013) and NSCLC
(Liu et al., 2016). RIOK3 has been associated with remodeling of
the cytoskeleton in hypoxia-driven metastases of breast cancer cells
(Singleton et al., 2015). Together with our identiﬁcation of RIOK1 as
an enhancer of oncogenic RAS signaling in C. elegans (Weinberg et al.,
2014), the aberrant expression of human RIO kinases in cancer, in par-
ticular in carcinoma entities with high frequencies of RAS mutations,
suggests a conserved role of RIO kinases in the RAS signaling network.
Therefore, we characterized the role of these ill-deﬁned atypical kinases
in various mammalian tumor cell lines by functional and proteomic ap-
proaches. We show that loss of RIOK1 expression speciﬁcally impairs
the phenotype of RAS-transformed colon-, lung- and breast cancer cells.
2. Material and Methods
2.1. Tissue Culture and Generation of Inducible Knockdown Cell Lines
The following cell lines were used in this study: NCI-H1299, MDA-
MB-231, HEK293T, Plat-E, Caco-2, RKO, SW480, HCT116, K562 and
MCF-10A. NCI-H1299, MDA-MB-231, SW480, RKO, HCT116, Caco-2,
HEK293T and Plat-E cell lines were cultivated in DMEM with 10% FCS.
K562 cells were cultivated in RPMI with 10% FCS. MCF-10A cells werecultivated as described previously (Herr et al., 2011). NCI-H1299 cells
were provided by the BIOSS toolbox, the central repository of the Centre
for Biological Signalling Studies, University of Freiburg. RKO cells were a
kind gift of Prof. Nils Blüthgen, Berlin (Fritsche-Guenther et al., 2011).
The source of all other cell lines has been described elsewhere
(Fritsche-Guenther et al., 2011; Herr et al., 2015; Herr et al., 2011; Leh-
mann et al., 2016;Wöhrle et al., 2013). Knockdown cell lineswere gener-
ated by lentiviral infection using the pTRIPZ system (Dharmacon).
Constructs used in this study: non-silencing: #RHS4743; shRIOK1_1:
#RHS4696-200770120, shRIOK1_2: #RHS4696-200769994, shRIOK1_3:
#RHS4696-200769020, shRIOK1_4: #RHS4696-200773349; shRIOK2: #
RHS4696-201898580; shRIOK3: # RHS4430-200288078. Cell lines were
established according to the instructions of the manufacturer and select-
ed with puromycin (AppliChem). Cells were maintained in respective
medium with puromycin. For experiments, cells were induced in medi-
um containing 0,5–1 μg/ml doxycycline (Sigma-Aldrich) without puro-
mycin. For all experiments knockdown was induced 3–4 days in
advance. Non-induced andnon-silencing cells served as controls; induced
non-silencing cells served as reference for quantiﬁcations.
2.2. Generation of cDNA Expression Vectors
The following cDNAexpression vectorswere used in this study: pBabe
luciferase, pMIBerry RIOK1myc WT, pMIBerry RIOK1myc D324A,
pMIBerry RIOK1myc D324N, pMIBerry RIOK1HAWT, pMIBerry RIOK3HA
WT, pCMV e.V., pCMVFLAG-IKK (WT, KD, CA). RIOK1 cDNA with C-
terminal myc-or HA-tag was ampliﬁed with Phusion polymerase (Ther-
mo Scientiﬁc) frompDONR223 RIOK1 (Addgene) and cloned in pMIBerry
(Röring et al., 2012) using the XhoI restriction site. D324 was mutated by
side-directed-mutagenesis using respective primers and Pfu ultra
plolymerase (Agilent Technologies). RIOK3 cDNA with C-terminal HA-
tag was ampliﬁed from pDONR223 RIOK3 (Addgene) with Phusion poly-
merase and cloned inpMIBerryusingXhoI andBamHI. ThepCMV IKK con-
structs were obtained from Addgene (Mercurio et al., 1997). The empty
pCMV control vector (e.V.) was generated from pCMV FLAG-IKK WT by
restriction digest with HindIII and ClaI, excising FLAG-IKK, followed by a
blunt ligation with T4. All constructs were veriﬁed by sequencing.
The following oligonucleotides were used in this study (in 5′ to 3′
direction):
RIOK1 XhoI fwd: TTCTCGAGGGCACCATGGACTACCGGCGGCTTCT
CATG.
RIOK1myc XhoI rev: TTCTCGAGGGGTTACAGGTCCTCCTCTGAGATCAG
CTTCTGCTCTTTGCCTTTTTTCGTCTTGGCTGTCTTCTCCTTTCTTTTTTTCAC
RIOK1HA XhoI rev: CCTCCTCGAGGGGTTAAGCGTAGTCTGGGACGTCG
TATGGGTATTTGCCTTTTTTCGTCTTGGCTGTCTTCTCCTTTCTTTTTTTCA
CATGTTT
RIOK3 XhoI fwd: TTGGCCTCGAGGGCACCATGGATCTGGTAGGAGTG
GCATCGCC
RIOK3 HA BamHI rev: CCCGGGGGATCCGTTGGATTAAGCGTAGTCTG
GGACGTCGTATGGGTATTCATCATATAGTAGTGGTGGGTCTCCATCA
TCTTTCAAAAATGAAGCAGC
RIOK1 D324A fwd: GCCAGACTTGTCCATGCAGCTCTCAGTGAATTTA
ACATG.
RIOK1 D324A rev: CATGTTAAATTCACTGAGAGCTGCATGGACAAGTCT
GGC
RIOK1 D324N fwd: CAGGATGCCAGACTTGTCCATGCAAATCTCAGTG
AATTTAACATGCTG
RIOK1 D324N rev: CAGCATGTTAAATTCACTGAGATTTGCATGGACA
AGTCTGGCATCCTG
2.3. Antibodies and Western Blot Analysis
Cell lysis, SDS-PAGE andWestern blot were performed as described
in (Herr et al., 2015). Blotted proteins were visualized and quantiﬁed
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cluded software.
Antibodies (with RRID, if available) used in this study were:
14-3-3 (H8) (Santa Cruz AB_626618); 9E10 myc (generated in-
house from the 9E10 hybridoma cell line (Evan & Hancock, 1985)), HA
3F10 (Roche Applied Science AB_390919), AKT (Cell Signaling
AB_329827); phospho-AKT(S473) (Cell Signaling AB_2315049); Aurora
A (Cell Signaling 12,100); Aurora B (BDAB_398396); Cyclin A2 (Cell Sig-
naling AB_2071958), Cyclin B1 (Cell Signaling 12,231); Cyclin D1 (Cell
Signaling AB_10839128), Cyclin E2 (Cell Signaling AB_2071197);
CDK1 (Cell Signaling AB_2074795), phospho-CDK1 (Y15) (Cell Signal-
ing AB_331460); FLAG (M2) (Sigma-Aldrich AB_439685), pIκBα S32
(Cell Signaling AB_561111), IκBα (Cell Signaling AB_331623); MTDH
(Invitrogen AB_2533475); Lamin B (D9V6H) (Cell Signaling 13,435);
P65 (Cell Signaling AB_10859369); phospho-P65 (Ser536) (Cell
Signaling AB_331284); RIOK1 (abcam AB_2042809); RIOK2 (abcam
AB_2042810); RIOK3 (SUDD (RS-31)) (Santa CruzAB_2178113);
Stathmin1 (Cell Signaling 3352); phospho-Stathmin1 (S38) (Cell Sig-
naling AB_10544408); Tubulin (B5-1-2) (Santa Cruz AB_628410). Sec-
ondary α-mouse HRP, α-rabbit HRP and α-goat HRP antibodies were
purchased from Santa Cruz. Bay 11–7082 was purchased from
SelleckChem.
Western Blots were developed with the PeqlabTM Fusion Solo and
densitometrically analyzedwith the Fusion software (ver. 16.08). Quan-
tiﬁcation for Western Blots is shown in Table S4.
2.4. Co-immunoprecipitation Studies
For co-immunoprecipitation studies, Plat-E cells (Morita et al., 2000)
were transfected with 8 μg expression vectors, lysed 48 h later and the
immunoprecipitation against the myc-tag was carried out as described
previously (Röring et al., 2012).
2.5. 3D Matrix Growth and Microscopy
Five thousand cells were seeded, grown in 2% Matrigel® (BD Biosci-
ence), cultivated andﬁxed as described previously (Herr et al., 2011). E-
Cadherin staining (BD Bioscience AB_397580), F-Actin staining
(Phalloidin Alexa 488 (Cell Signaling 8878)) and DAPI ProLong® Gold
(LifeTechnologie P36931) were applied according to manufacturer's
protocol.
Living ﬂuorescent cells, cultured conventionally or in 3D matrix,
were imaged with the ZEISS AxioObserver Z1 wide ﬁeld microscope
with a 10× A-Plan 0.25 air objective connected to an AxioCamMRm
camera. For ﬁxed cells and immuno-ﬂuorescent stainings, the ZEISS
AxioObserver Z1 plus ApoTome2 was used. Images were taken with a
10×A-Plan 0.25 air objective or a 40×PlanNeoFluar 1.3 oil objective, re-
spectively. For IHC images the ZEISS Axioskop2 with a 10×
PlanNeoFluor 0.17 air objective was used.
2.6. Mass Spectrometry Analysis of SILAC Labeled NCI-H1299 Cells
2.6.1. Cell Culture and Stable Isotope Labeling
Cells were subcultured and passaged in SILAC-DMEM (Thermo Fish-
er Scientiﬁc, Langenselbold, Germany) supplementedwith 10% dialyzed
FBS (Gibco, Invitrogen), 1% L-glutamine (PAN Biotech), 42 mg/l L-
arginine (Sigma-Aldrich), 73 mg/l L-lysine (Sigma-Aldrich) and
82 mg/l proline (Sigma-Aldrich). According to the experimental setup
cells were cultured and fully labeled for two weeks in the same way
but through incorporation of L-arginine-13C6-15 N4 and L-lysine-
13C615N2 (Arg10 Lys8; Cambridge Isotope Laboratories).
2.6.2. MS Sample Preparation
Sampleswere lysed in SDS-PAGE loading buffer, reducedwith 1mM
DTT (Sigma-Aldrich) for 5 min at 95 °C and alkylated using 5.5 mM
iodoacetamide (Sigma-Aldrich) for 30 min at 25 °C in the dark. Proteinmixtures were separated by SDS-PAGE using 4–12% Bis-Tris mini gradi-
ent gels (NuPAGE, Life Technologies). The gel lanes were cut into 10
equal slices, which were in-gel digested with trypsin (Promega, Mann-
heim, Germany) (Shevchenko et al., 2006) and the resulting peptide
mixtures were processed on STAGE tips as described (Rappsilber et al.,
2007).2.6.3. MS
Mass spectrometricmeasurementswere performed on LTQOrbitrap
XL mass spectrometer (Thermo Fisher Scientiﬁc, Bremen, Germany)
coupled to an Agilent 1200 nanoﬂow-HPLC (Agilent Technologies
GmbH, Waldbronn, Germany) essentially as described in (Sprenger
et al., 2013). HPLC-column tips (fused silica) with 75 μm inner diameter
(NewObjective, Woburn, MA, USA)were self-packedwith Reprosil-Pur
120 ODS-3 (Dr. Maisch, Ammerbuch, Germany) to a length of 20 cm.
Samples were applied directly onto the column without pre-column.
A gradient of A [0.5% acetic acid (high purity, LGC Promochem, Wesel,
Germany) in water] and B [0.5% acetic acid in 80% ACN (LC-MS grade,
Wako, Germany) in water] with increasing organic proportion was
used for peptide separation (loading of sample with 2% B; separation
ramp: from 10% to 30% B within 80 min). The ﬂow rate was
250 nl/min and for sample application 500 nl/min. The mass spectrom-
eter was operated in the data-dependent mode and switched automat-
ically betweenMS (max. of 1 × 106 ions) andMS/MS. EachMS scanwas
followed by amaximum of ﬁveMS/MS scans in the linear ion trap using
normalized collision energy of 35% and a target value of 5000. Parent
ions with a charge state from z = 1 and unassigned charge states
were excluded for fragmentation. The mass range for MS was m/z =
370 to 2000. The resolution was set to 60,000. Mass-spectrometric pa-
rameters were as follows: spray voltage 2.3 kV; no sheath and auxiliary
gas ﬂow; ion-transfer tube temperature 125 °C.2.6.4. Identiﬁcation of Proteins and Protein Ratio Assignment Using
MaxQuant
The MS raw data ﬁles were uploaded into the MaxQuant software
version 1.3.05 (Cox & Mann, 2008), which performs peak detection,
SILAC-pair detection, generates peak lists of mass error corrected pep-
tides and data base searches. A full length uniprot database (based on
uniprot human version July 2012) was employed together with reverse
annotations of all sequences. Carbamidomethylcysteinewas set as ﬁxed
modiﬁcation, methionine oxidation and protein amino-terminal acety-
lation were set as variable modiﬁcations. Double SILAC was chosen as
quantitation mode. Three miss cleavages were allowed, enzyme speci-
ﬁcity was trypsin/P + DP, and the MS/MS tolerance was set to 0.5 Da.
The average mass precision of identiﬁed peptides was in general
b1 ppmafter recalibration. Peptide listswere further used byMaxQuant
to identify and relatively quantify proteins using the following parame-
ters: peptide, and protein false discovery rates (FDR) were set to 0.01,
maximum peptide posterior error probability (PEP) was set to 0.1, min-
imum peptide length was set to 7, minimum number of peptides for
identiﬁcation and quantitation of proteins was set to two of which one
must be unique, and identiﬁed proteins have been re-quantiﬁed. The
“match-between-run” option (2 min) was used.2.6.5. Data Analysis
Data were loaded into the freely available Perseus software and log2
transformed (Cox et al., 2011). Signiﬁcance B (permutation based
FDR ≤ 0.05) was used to identify signiﬁcantly up-and down regulated
proteins between control and knockdown cells. To address the biologi-
cal implications of identiﬁed proteins they were analyzed by STRING
(Franceschini et al., 2013) for interactions (default parameters) and
resulting networks were visualized by cytoscape (http://www.
cytoscape.org/).
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Five hundred cells were seeded in 6 well plates and grown for up to
13 days. Cell colonies were ﬁxed and stained with Giemsa (Carl-Roth).
Plates were imaged and cell density per well was determined by pixel
density measurement using Photoshop CS2.
2.8. Luciferase Reporter Assay
Cells were seeded in low density (2–4 × 104) in 24 well plates,
allowed to attach and transfected with 10 ng pRL CMV Renilla (kindly
provided by Andreas Hecht, IMMZ Freiburg) and 500 ng 2xHIVκBLuc
Fireﬂy (Minguet et al., 2005). In the case of IKK2 co-transfection, 1 μg
pCMV empty vector or FLAG-IKK (WT/KD/CA) was used. After 48 h
cells were lysed in luciferase lysis buffer and luciferase activity was de-
termined as described in (Rönsch et al., 2015).
2.9. MTT Cell Viability Test
One to three thousand cells were seeded in 96-Well plates and
grown for up to four days. For MTT measurement, medium was ex-
changed to MTT solution (mediumwith 0.45 mg/ml Thiazolyl Blue Tet-
razolium Bromide (Sigma-Aldrich)). After incubation at 37 °C for 2 h,
medium was aspirated and formed crystals were dissolved in 150 μl
DMSO. Absorption at 590 nm was measured with a plate reader
(Tecan plate reader). MTT activity was determined each day beginning
with day 0 and normalized to day 0 or normalized to NS dox.
2.10. Caspase 3 Cell Death Assay
For caspase 3 assay, cells were lysed as described previously (Herr et
al., 2015) and a total amount of 20 μg protein was mixed with 90 μl of
assay buffer (100 mM HEPES pH 7.4, 10 mM DTT, 60 μM Ac-DEVD-
AMC). Fluorescence was measured at 460 nm every 2 min for 60 min
at 37 °C. Slopes of caspase activities were calculated and compared.
2.11. Mouse Maintenance, Handling and Xenografts
Rag2−/−;γc−/−mice on a BALB/C backgroundwere purchased from
the local stock of the animal facility at Freiburg University Medical Cen-
ter and housed in the speciﬁc pathogen-free barrier facility of the Uni-
versity Medical Center Freiburg in accordance with the institutional
guidelines and approved by the local animal ethics committee (G-13/
116). For xenograft experiments NCI-H1299 non-silencing or shRIOK1
pBabe luciferase cells were either injected on day 0 subcutaneously
into the ﬂanks (5 × 105) or intravenously into the tail vain (1 × 105)
of Rag2−/−,γc−/−mice, between 6 and 12 weeks of age. For Xeno-
graft experiments, tumor growth was monitored by palpation and reg-
ular BLI and knockdown was initiated by application of doxycycline via
the drinkingwater (2mg/ml) after palpable tumors formed. For metas-
tasis formation assays, pre-induced cells (-4d) were injected into the
tail vein and cells were followed by regular BLI. Mice were sacriﬁced
after reaching the biological endpoint and xenografts and lungs were
isolated and ﬁxed in 4% paraformaldehyde. 2 μm sections were de-
parafﬁnized and stained with hematoxylin and eosin or RIOK1.
2.12. Histological and Immunohistochemical Analyses of Xenograft and Hu-
man Tissue Specimens
Xenografts (N= 15) and lung metastases (N= 54) were formalin
ﬁxed and parafﬁn embedded (FFPE). Serial tissue slices of 2 μm thick-
ness were prepared and stained for Hematoxylin and Eosin (H&E) and
RIOK1 (AB_2042809; 1:1500). After one night at 56 °C incubation a
heat-induced antigen retrieval was performed at 97–99 °C for a period
of 40 min in pH 6.1 using Dako antigen retrieval buffer S1699. Primary
antibody was incubated at room temperature for 30 min by usingEnVision™ FLEX Kit K8012 (Dako, Autostainer Plus). All slides were
counterstainedwith hematoxylin, dehydrated in ascending alcohol con-
centrations and covered.
2.12.1. Tissue Specimens
FFPE tissue specimens from primary non-small cell lung cancers
(N= 30) were re-classiﬁed according to the actual WHO Classiﬁcation
of Tumors of the Lung, Pleura, Thymus and Heart (Travis et al., 2015) as
follows: adenocarcinoma (AC) (N= 15) and squamous cell carcinoma
(SCC) (N= 15), (see also Table S3). Staining for RIOK1 was performed
as described above.
FFPE tissue specimens from primary breast carcinomas (N = 22)
andmatched normal breast tissue (N=22)were re-classiﬁed according
to the actual WHO Classiﬁcation of Tumors of the Breast (Lakhani et al.,
2012) as follows: no special type (NST) (N=14), invasive lobular (N=
3), mucinous (N = 2), tubular (N = 2) and medullary (N = 1). Addi-
tionally, hormone receptor status and Her2neu status were – based on
stained slides from routine diagnostics - re-classiﬁed according to the
actual guidelines (Lakhani et al., 2012) (see also Table S3). A tissue mi-
croarray (TMA) consisting of these 22 primary breast carcinomas and
their matched normal breast tissue was stained for RIOK1 as described
above. Ethical approval was obtained from the local institutional ethics
committee (University of Freiburg, Ethik-Kommission, ID #234/13).
2.13. Statistical analysis
Quantitative data are presented asmean± SEM.Multiple group and
pair-wise comparisons were performed by Mann-Whitney (two-
tailed), Student t-test (two-tailed), paired t-test, two way ANOVA or
Chi-square test, respectively, using GraphPad Prism 6. A p-value of
≤0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Knockdown of RIOK1 in Cancer Cells Inhibits Proliferation and Impairs
Growth in 3D Cell Culture
The expression of RIOK1 is hardly characterized at the mRNA and
protein level in cancer. Therefore, we ﬁrst analyzed RIOK1 mRNA ex-
pression in normal and cancer tissue in silico using the Oncomine
mRNA database (Fig. 1a). In line with previously published data on 22
primary tumors (Line et al., 2002), our analysis showed that RIOK1
mRNA levels are, compared to healthy tissue, elevated in gastric adeno-
carcinoma (Fig. 1b), cecal adenocarcinoma, colorectal adenoma and co-
lorectal adenocarcinoma (Fig. 1c). Next, we evaluated the expression of
all three RIO kinase members at the protein level in tumor cell lines de-
rived from colon-, breast- and non-small cell lung cancer (Fig. 1d). We
observed that the three RIO paralogues are expressed to various de-
grees. Based on our previous study showing a genetic collaboration be-
tween RIOK1 and oncogenic RasG13E in C. elegans (Weinberg et al.,
2014), we chose cancer cell lines with high RIO kinase expression and
gain-of-function mutations in NRAS (NCI-H1299 (non-small cell lung
cancer)) or KRAS (MDA-MB-231 (breast cancer), SW480 and HCT116
(colon cancer)) for knockdown studies to delineate the isoform-
speciﬁc contributions to their transformed phenotypes. All cell lines
were transduced with lentiviral vectors allowing the doxycycline
(dox) inducible expression of the red ﬂuorescent protein tRFP along
with the expression of either shRNAs targeting RIOK1-3 or a non-
silencing (NS) control shRNA. For RIOK1, several shRNAs were tested
in NCI-H1299 and MDA-MB-231 cells resulting in different knockdown
efﬁcacies (Fig. S1a and Table S4). Unless stated otherwise, the most ef-
fective shRNA for RIOK1 (shRIOK1_3) was chosen for the following ex-
periments. First, we analyzed the lung- and breast cancer cell lines NCI-
H1299 and MDA-MB-231, respectively. After establishing stable induc-
ible knockdown cell lines (Fig. 2a),we investigated colony formation ca-
pacity after depletion of the individual RIOK isoforms. We observed
Fig. 1. RIOK1 is overexpressed in colorectal and gastric cancer. (a) Oncomine™ based mRNA expression analysis for human RIOK1 in different cancer entities comparing normal versus
cancer tissue samples. (b and c) Oncomine™ based detailed mRNA expression analyses for gastric (b) and colorectal (c) cancer demonstrating overexpression of RIOK1 in cancer
versus normal tissue. Signiﬁcance was calculated comparing mRNA expression in normal tissue (light blue) versus cancerous tissue (dark blue). (d) RIO kinase protein expression
analysis of different cancer cell lines using the indicated antibodies. 14-3-3 serves as loading control. Arrows indicate speciﬁc bands for RIOK1 and RIOK3.
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Fig. 2.Knockdownof RIOK1 in RAS-transformed lung- and breast cancer cell lines inhibits proliferation, invasiveness andmetabolism. (a) RepresentativeWestern blot analysis conﬁrming
RIOK1, RIOK2 and RIOK3 knockdown for NCI-H1299 (N= 4) and MDA-MB-231 cells (N= 2). (b) Colony formation assays of NCI-H1299 and MDA-MB-231 cells. Formed colonies were
stained after 10 days and cell densitywas determined. Representative pictures are shown. Data is represented asmean±SEMwith *** for p b 0.001 and **** for p b 0.0001 by ordinary two-
way ANOVA (Dunnett (H1299) and Tukey (MDA-MB-231)) compared to non-sil. dox. NCI-H1299 N= 6 for NS and shRIOK1, N= 2 for shRIOK2 and 3. MDA-MB-231 N= 4 for NS and
shRIOK1, N= 1 for shRIOK2 and 3. (c) NCI-H1299 and MDA-MB-231 cells were seeded in 2% Matrigel and grown for up to 14 days. Scale bars: 200 μm. (d) MTT assay sequentially
measured for 4 days for NCI-H1299 and MDA-MB-231 cells. Data is represented as mean ± SEM by multiple t-test; N= 3, each. (See also Fig. S1).
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Fig. 3.Knockdown of RIOK1 in RAS-transformed colon cancer cell lines inhibits proliferation andmetabolism. (a) Representative RIOK1 knockdownWestern blot analysis for SW480 cells
(N=3). (b) Colony formation assays of SW480 cells. Formed colonieswere stained after 7 days and cell densitywas determined. Representative pictures are shown. Data is represented as
mean ± SEM with ** for p b 0.01 by ordinary two-way ANOVA (Tukey) compared to non-sil. dox. N= 3. (c) SW480 cells were seeded in 2% Matrigel and grown for 13 days. Scale bar:
200 μm. (d) MTT assay measured on day 3 for SW480 cells. Data is represented as mean ± SEM; N = 2. (e) RIOK1 knockdown Western blot analysis for HCT116 cells (N = 1).
(f) Colony formation assays of HCT116 cells. Formed colonies were stained after 10 days and cell density was determined. Representative pictures are shown. Data is represented as
mean ± SEM with * for p b 0.05 by ordinary two-way ANOVA (Dunnett) compared to non-sil. dox; N= 4. (g) HCT116 cells were seeded in 2% Matrigel and grown for 18 days. Scale
bars: 200 μm. (h) MTT assay measured on indicated timepoints and normalized to day 0 for HCT116 cells. Data is represented as mean ± SEM with * for p b 0.05 by two-way ANOVA
(Tukey); N= 3.
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86 F. Weinberg et al. / EBioMedicine 20 (2017) 79–97fewer and smaller colonies in both analyzed cell lines compared to the
NS control or to the isogenic non-induced controls after RIOK1 depriva-
tion (Fig. 2b). Interestingly, knockdown of RIOK2 or RIOK3 did not yield
as remarkable growth arrests (Fig. 2b), despite equally strong reductionin RIOK2 and RIOK3 expression (Fig. 2a). This demonstrates that loss of
RIOK1 cannot be compensated by the other paralogs.
As the growth behavior of carcinoma cells can strongly differ be-
tween conventional tissue culture and 3D matrix growth (Debnath
87F. Weinberg et al. / EBioMedicine 20 (2017) 79–97et al., 2003; Herr et al., 2011), we assessed the effects of RIOK depletion
in three-dimensional (3D) matrices. Again, reduced growth was only
observed upon RIOK1 deprivation (Fig. 2c). RIOK1 depleted spheres
displayed rounder shapes, less ﬁlopodia-like structures and protrusions.
Next, we investigated the metabolic activity of NCI-H1299 and
MDA-MB-231 cells upon loss of RIOK1 by sequential MTT measure-
ments over four days (Fig. 2d). Fromday three onwards, RIOK1 deﬁcient
cells displayed a signiﬁcantly reduced metabolic activity compared to
the NS control cells or non-induced cells. Importantly, the ability to re-
duce proliferation in conventional and 3D matrix culture as well as the
metabolic activity of NCI-H1299 and MDA-MB231 cells correlated
with the knockdown efﬁcacies of the distinct RIOK1 shRNAs (Fig. S1b–
d). As we observed only an insigniﬁcant increase in caspase-3 activity
upon RIOK1 knockdown (Fig. S1e), we exclude cell death asmain driver
for the observed phenotypes.
Next, we analyzed the cellular response of the K-Ras-driven colorec-
tal cancer cell lines HCT116 and SW480 upon RIOK1 depletion (Fig. 3).
After having established inducible shRIOK1 and control cell lines for
SW480 cells (Fig. 3a), we analyzed their proliferation capacity in 2D
and 3D culture after RIOK1 depletion. As shown in Fig. 3b, SW480 cells
formed fewer colonies in conventional culture and were impaired in
3D matrix growth (Fig. 3c), although the growth arrest appeared not
as profound as observed inMDA-MB-231 or NCI-H1299 cells. Metabolic
activity was also impaired upon RIOK1 knockdown (Fig. 3d). Similar re-
sults were obtained for HCT116 cells (Fig. 3e). Again, cell growth ap-
peared more strongly impaired in conventional culture (Fig. 3f) as
compared to 3Dmatrix growth (Fig. 3g). Accordingly, cell metabolic ac-
tivity was again reduced upon RIOK1 depletion (Fig. 3h). Similar to
MDA-MB-231 and NCI-H1299 cells, knockdown with shRIOK1 knock-
down construct #3 led to stronger growth arrest, which again correlat-
ed with the knockdown efﬁcacy (Figs. S1 and 3e–h). It should be noted
that, while our studywas in progress, Marjon et al. (2016) also observed
impaired proliferation of HCT116 cells in 2D culture upon RIOK1 knock-
down with shRNA constructs unrelated to ours in terms of target se-
quence and vector design.
The severe effect of RIOK1 depletion could reﬂect a strong necessity
for this atypical kinase in fundamental cellular processes rather than a
speciﬁc requirement in RAS-mediated transformation. Therefore, we
analyzed the inﬂuence of RIO kinase knockdown on well-
differentiated adenocarcinoma cell line Caco-2, the BRAFV600E and
PI3KCAH1047R-driven colorectal cancer cell line RKO and the Bcr-Abl
driven leukemia cell line K562 (Fig. S2). Knockdown of RIOK1 in Caco-
2 cells (Fig. S2a) did neither affect colony formation (Fig. S2b) nor
growth in three-dimensional matrix (Fig. S2c) and metabolic activity
(Fig. S2d). Likewise, knockdown of RIOK1 did not inhibit 3D growth of
RKO cells (Fig. S2e and f) and did not alter cell viability of the Bcr-Abl-
driven K562 leukemia cell line (Fig. S2g and h). This indicates that
RIOK1 depletion is not always cytostatic.
So far, we have observed exclusively strong effects of RIOK1 deple-
tion in established cancer cell lines carrying an endogenous RASmuta-
tion. Therefore, we were interested to investigate the effects of RIOK1
depletion in an isogenic system in which oncogenic RAS was not
expressed a priori, but was acutely introduced only a few passages be-
fore RIOK1 depletion. To this end, we turned to the non-tumorigenic
human mammary epithelial cell line MCF-10A, which lacks mutations
in RAS (or its effectors) and has been spontaneously immortalized by
MYC ampliﬁcation and loss of p16INK4 and p14ARF (Debnath et al.,
2003). In 3D culture, these cells form so-called acini in a well-deﬁned
morphogenetic process that integrates multiple biological processes inFig. 4.KRAS-induced transformation of epithelial MCF-10A can be partially prevented by knock
1). (b and c) Colony formation assays of MCF-10A KRAS cells. Formed colonies were stained a
represented as mean ± SEM with **** for p b 0.0001, *** for p b 0.001, ** for p b 0.01 and *
indicated timepoints for MCF-10A KRAS cells. Data is represented as mean ± SEM with **
(e) MCF-10A KRAS cells were seeded in 2% Matrigel and grown for 28 days. Scale bars: 200
cells. Note that these are lost upon RIOK1 knockdown (white arrows) (See also Fig. S3).a coordinated spatio-temporal fashion. Potent oncogenes such as RAS
mutants perturb acinar morphogenesis by multiple processes (Herr
et al., 2011; Li et al., 2010). Therefore, we infected MCF-10A cells with
pMIG retroviral expression vectors encoding GFP, either singly or in
combinationwith KRASG12V (Fig. 4a). As shown in Fig. 4b and c, overex-
pression of KRASG12V in MCF-10A cells induced growth arrest in con-
ventional cell culture. Knockdown of RIOK1 reduced the growth of
empty vector and KRASG12V expressing cells, whereas the NS construct
had no inﬂuence on colony growth. Importantly, this growth arrest
upon RIOK1 loss was stronger in KRASG12V expressing cells. Related to
this ﬁnding, cell metabolic activity of RIOK1 deﬁcient cells was reduced
in empty vector and KRASG12V expressing cells on day 3 and 4 after
seeding, too (Fig. 4d). When cultured in 3D matrix, MCF-10A KRASG12V
high expressing cells formed colonies with invasive protrusions
(Figs. 4e and S3a, black arrows). A similar invasive 3D phenotype has
been described for oncogenic H-Ras (Li et al., 2010). In contrast to con-
ventional growth, knockdown of RIOK1 did neither impair the growth
nor the overall structure of the formed acini in empty vector expressing
cells (Figs. 4e 1st and 3rd panel, S3a). Importantly and in line with our
results in NCI-H1299 andMDA-MB-231 cells (Fig. 2c), RIOK1 deﬁciency
prevented the formation of invasive protrusions in KRASG12V expressing
MCF-10A cells (Figs. 4e and S3a, white arrows). Likewise, the typical
loss of contact inhibition induced by oncogenic RAS was partially
reverted by the loss of RIOK1 expression (Fig. 4e, 2nd and 4th panel).
We further analyzed MCF-10A acini by E-Cadherin staining (Fig. S3b
and S3c), a marker often used to assess the acinar structure of MCF-
10A cells (Herr et al., 2011). Knockdown of neither RIOK1, 2 nor 3 did
alter E-Cadherin expression or MCF-10A acini formation compared to
non-silencing expressing spheres (Fig. S3c).
In summary, our data demonstrates that RIOK1 knockdown reverts
the strong 2D and 3D growth and invasion phenotypes of four distinct
RAS-driven carcinoma cell lines derived from three tumor entities as
well as of MCF-10A cells transformed by KRASG12V. This suggests that
the growth and invasion promoting function of RIOK1 is of particular
relevance for RASmutant cells.
3.2. A Mass-spectrometric Approach Identiﬁes Effector Proteins of RIOK1
Besides its important role in ribosomal biogenesis and as substrate
recruiting protein of the PRMT5 complex (Guderian et al., 2011), no
cancer-related molecular functions are known for mammalian RIOK1.
Therefore, we used a SILAC-based mass-spectrometric (MS) approach
(Fig. 5a and Table S1) and an antibody array (Table S2) to gain more in-
sights into the protein network controlled by RIOK1 in NCI-H1299. To
this end, the proteome of RIOK1-expressing cells was compared to
that of RIOK1 depleted cells. We quantiﬁed N2800 proteins and identi-
ﬁed signiﬁcant changes based on SILAC ratio distributions (Fig. 5b; sig-
niﬁcance B, permutation based FDR b 0.05) (Cox & Mann, 2008).
Signiﬁcantly deregulated proteins were linked to known interactions
using STRING DB and respective protein networks were generated
(Fig. 5c) (Franceschini et al., 2013). Upon RIOK1 knockdown, several
known pre-40S ribosomal subunit proteins were upregulated
(Turowski et al., 1997; Zemp & Kutay, 2007), including RIOK2 (Fig. 5b
and c). Down-regulated proteinswere associated with cell cycle (Cyclin
B1, Anillin, TYMS, UBE2S) ormetabolic activity (G0S2, SCD-1, ASNS). In-
terestingly, the oncogene product Metadherin (MTDH), which pro-
motes AKT- and NF-κB signaling and metastasis formation (Emdad
et al., 2006; Haug et al., 2015; Khuda et al., 2009; Lee et al., 2008;
Sarkar et al., 2008), was reduced in expression. Analysis of proteinsdown of RIOK1. (a) RIOK1 knockdownWestern blot analysis for MCF-10A KRAS cells (N=
fter 14 days and cell density was determined. Representative pictures are shown. Data is
for p b 0.05 by ordinary two-way ANOVA (Tukey); N = 3. (d) MTT assay measured on
* for p b 0.001, ** for p b 0.01 and * for p b 0.05 by two-way ANOVA (Tukey); N = 3.
μm. Black arrows indicate invasive protrusion formed in the GFP/KRASG12V transformed
Fig. 5. SILAC-basedmass-spectrometric approach and validation of RIOK1 effector proteins. (a)NCI-H1299 shRIOK1 cellswere labeled by SILAC and induced or left untreated 6 days prior to
lysis. Lysates were mixed and analyzed by LC-MS/MS. (b) SILAC-based fold-changes of up- and down-regulated proteins upon RIOK1 knockdown are shown. Red rhombuses indicate
signiﬁcantly changed proteins upon knockdown (signiﬁcance B, permutation based FDR b 0.05). (c) Protein-protein interaction network for signiﬁcantly regulated proteins upon Riok1
depletion. (d) Representative Western blot analysis and quantiﬁcations of NCI-H1299 cells for cell cycle proteins and (e) RIOK1 effector proteins N = 4; *** for p b 0.001; ** for
p b 0.01 and * for p b 0.05; unpaired two-tailed t-test (mean ± SEM). (See also Figs. S4 and S5).
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showed an increased phosphorylation of Stathmin1 (S25/38) and La-
related protein1 (LARP1; S774). Stathmin1 promotes tumor growth
and metastases by microtubule-dependent and independent mecha-
nisms and is required for invasive growth in 3D neuroblastomamodels(Fife et al., 2016). LARP1 contributes to cell cycle initiation and progres-
sion (Burrows et al., 2010). In conclusion, we show that depletion of
RIOK1 affects the expression and phosphorylation status of several pro-
teins involved in ribosomal biogenesis, cell cycle progression, metabolic
activity, NF-κB signaling and metastases.
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Viability
To validate theMS data,we analyzed the abundance of the identiﬁed
RIOK1 effector proteins in our cell linemodels. Startingwith NCI-H1299
cells, we ﬁrst conﬁrmed the role of mammalian RIOK1 in cell cycle pro-
gression. RIOK1 knockdown resulted in decreased expression of Cyclin
A2, Cyclin B1, Aurora kinases A and B as well as in a clear decrease of
CDK1 phosphorylation (Y15) (Fig. 5d). Furthermore, we conﬁrmed the
MS predicted increase of RIOK2 expression upon RIOK1 knockdown
(Fig. 5e), which was accompanied by a robust electrophoretic mobility
shift. In addition to decreasedMTDH levels, we also noticed a signiﬁcant
downregulation of RIOK3 expression. The expression of Stathmin1 was
not altered, but its phosphorylation on Ser38, a site recently shown to be
important for breast cancer cell invasion (Kuang et al., 2015; Kuang
et al., 2016), was clearly reduced (Fig. 5e).
Next, we conﬁrmed the inﬂuence of RIOK1 knockdown on its identi-
ﬁed effectors in our other cellular systems (Figs. S4 and S5). We detect-
ed the increased expression and electrophoretic shift for RIOK2 and the
decreased expression for RIOK3 upon RIOK1 knockdown in all cell lines
except for K562 and MCF-10A KRASG12V cells. This suggests that
the three RIOK isoforms regulate each other, or are controlled in their
expression due to their essential consecutive roles in ribosomal
biogenesis.
For the other effectors, we observed a segregation between RAS-
driven and non-RAS-driven cancer cells on the one hand and between
colorectal and non-colorectal cells on the other hand. Whereas Cyclin
B1 was reduced in expression in most cell lines except for SW480,
MCF-10A and K562 cells, Cyclin A2 was only reduced in its expression
in MDA-MB-231 cells. Phosphorylation of CDK1 (Y15), Stathmin1
(S38) and MTDH expression were clearly reduced in MDA-MB-231
and MCF-10A KRASG12V cells, which was not the case for the other cell
lines. Most importantly, RIOK1 knockdown in MCF-10A empty vector
control cells did not provoke the expression changes observed in MCF-
10A KRASG12V cells, emphasizing that RIOK1 expression is critical for
KRASG12V signaling. Although all RAS-driven cell lines reacted upon
RIOK1 knockdown with decreased growth and cell metabolism
(Figs. 2–4), only NCI-H1299, MDA-MB-231 and MCF-10A KRASG12V
cells share regulation of identiﬁed RIOK1 effectors on the protein level.
This resultmay indicate different cellular functions for RIOK1 in colorec-
tal cancer cell lines, compared to lung- and breast cancer cells.
3.4. Invasive Protrusions Rely on RIOK1 Expression and NF-κB Activity
It was previously shown thatMTDH is a positive regulator of the NF-
κB pathway in various cancer entities by being an IKK substrate and pro-
moter of phosphorylation-dependent IκB degradation (Alexia et al.,
2013; Krishnan et al., 2015; Shi&Wang, 2015). AsMTDHexpression de-
creases upon RIOK1 depletion and because oncogenic RAS promotes
NF-κB activity (Basseres et al., 2014), we asked whether RIOK1 deple-
tion impairs NF-κB signaling. First, we detected a diminished basal NF-
κB activity upon RIOK1 knockdown in NCI-H1299 and MDA-MB-231
cells by using a luciferase reporter for transcriptionally competent NF-
κB (Fig. 6a). To further narrow down at which step RIOK1 depletion af-
fects the NF-κB pathway, we co-expressed different IKK2 constructs to-
gether with the NF-κB luciferase reporter in the NCI-H1299 system
(Fig. 6b and c). Expression of wildtype IKK2 neither increased basal
levels of NF-κB activity nor was able to rescue the reduction in pathway
activity by RIOK1 depletion. Expression of the kinase inactive IKK2K44M
mutant reduced pathway activity under all conditions, whereas the ex-
pression of IKK2S177/181E, a constitutively activemutant, increased path-
way activation in all cell lines. Still, IKK2S177/181E was not able to
augment pathway activity in RIOK1 deﬁcient cells to the same extent
as in the non-induced culture or dox-treatedNS cells. To further address
at which level RIOK1 depletion impairs NF-κB activity, we stimulated
NCI-H1299 RIOK1 knockdown and NS control cells with TNFα in thepresence or absence of Bay 11-7082, an IKK inhibitor (Strickson et al.,
2013), and analyzed the abundance of key pathway components in
the cyto- and nucleoplasm (Fig. 6d and e). Under basal conditions, we
observed a trend (p= 0.089) for increased levels of IκBα, the negative
regulator of NF-κB signaling upon RIOK1 depletion (Fig. 6d, lane 2).
Moreover, RIOK1 deﬁcient cells displayed signiﬁcantly less phosphory-
lation of IkBa at S32 compared to the control cells (Fig. 6e lane 6).
These data suggest impaired IkBa degradation in RIOK1 depleted cells.
In line with this, RIOK1 depleted cells displayed less nuclear p65/NF-
κB (Fig. 6d, lane 10). As expected, Bay 11-7082 stabilized IκBα expres-
sion under both basal and TNFα stimulated conditions and strongly im-
paired p65 phosphorylation and nuclear accumulation (Fig. 6d, lanes
12–16). However, RIOK1 abundance had no inﬂuence on the TNFα-
induced activation of the pathway, suggesting that the strong TNFα sig-
nal also activated RIOK1 independent pathways to IκBα phosphoryla-
tion. The impaired pathway activation by Bay 11-7082 was also not
further enhanced by combination with RIOK1 knockdown. Thus, in
line with the identiﬁcation of MTDH as an IKK complex component
and substrate (Krishnan et al., 2015), we place the contribution of
RIOK1 toNF-κB signalingupstreamof IκBαdegradation, probably paral-
lel to the IKK complex.
Next, we assessed the effect of NF-κB pathway inhibition on the in-
vasive phenotype of NCI-H1299 cells. In 3D cultures of NCI-H1299
cells, the constant inhibition of the NF-κB pathway resulted in a similar
phenotype as provoked by RIOK1 knockdownwith spheres displaying a
smaller diameter and a reduction of invasive protrusions (Fig. 6f). In
contrast to the signaling analysis, this phenotype was further enhanced
by combination of Bay 11-7082 treatment with RIOK1 knockdown.
RIOK3 has been implicated in the regulation of actin ﬁlaments of
breast cancer cells, especially in the context of hypoxic regulation
(Singleton et al., 2015). We therefore analyzed protrusion formation
for the NCI-H1299 cells grown in 3D matrix displayed in Fig. 6f. RIOK1
deﬁcient cells showed reduced F-Actin expression and a localization of
F-Actin at the cell membranes (Figs. S6 and S7). In contrast, NS and
non-induced shRIOK1 cells formed protrusions with branching
ﬁlopodia-like structures with high levels of F-actin throughout the cell
(Figs. S6 and S7). Furthermore, RIOK1 depletion as well as Bay 11-
7082 largely reduced the amount of ﬁlopodia-like structures. Taken to-
gether, these data suggest that RIOK1 activates NF-κB signaling at the
level of the IKK complex and thereby augments the invasive growth be-
havior of NCI-H1299 cells.
3.5. RIOK1 Promotes the Formation of Metastases to the Lung In Vivo
Next, we analyzed the requirement of RIOK1 for invasive cell be-
havior in vivo. In a pilot xenograft experiment, we investigated sub-
cutaneous tumor growth of NCI-H1299 cells. Non-induced NS and
shRIOK1 cells were injected into the ﬂanks of immunocompromised
Rag2−/−γc−/− mice and knockdown of RIOK1 was induced once
palpable tumors arose. The growth of the inoculated subcutaneous
tumors did not differ between NCI-H1299 RIOK1 knockdown and
NS control cells, although histological analyses revealed less meta-
static burden in the lung (Fig. S8a–c). Western blot analysis con-
ﬁrmed the sustained knockdown of RIOK1 in isolated xenografts
(Fig. S8d). Histological staining with H&E and a human speciﬁc
RIOK1 antibody (Fig. S8e) were performed with NCI-H1299 xeno-
grafts. This showed that the xenografts formed by NS cells were char-
acterized by increased cellularity and presence of mitoses/metaphases
as compared to those derived from induced NCI-H1299 shRIOK1 cells
(Fig. S8f).
To investigate the metastatic potential of NCI-H1299 cells with or
without RIOK1 expression in mice in more detail, the cells were labeled
by luciferase expression and injected either into the ﬂanks or into the
tail vein of Rag2−/−;γc−/− mice. Luciferase positive NCI-H1299 lung
cancer cells were followed by consecutive bioluminescence imaging
(BLI). In the case of subcutaneous (s.c.) injection, knockdown of RIOK1
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grafts were detectable for both cell lines in all mice. BLI and tRFP signal
analyses did not show any difference in primary tumor growth (Fig.
S9a–c). Moreover, the weight of the injected mice was not alteredbetween the groups (Fig. S9d). These observations are in line with our
pilot study (Fig. S8). Strikingly, RFP ﬂuorescence analyses of the isolated
lungs reported metastasis formation only for NCI-H1299 NS control cell
injectedmice (Fig. S9e and f). Again,Western blot analysis of the formed
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(Fig. S9g).
Next, we conducted tail vein injection of induced NCI-H1299
shRIOK1 andNS control cells to answer the questionwhether RIOK1 ex-
pression is necessary to enable circulating cells to colonize distinct or-
gans (Fig. 7). Indeed, NCI-H1299 cells expressing the NS shRNA- or the
non-induced shRIOK1 construct effectively colonized to the lungs as an-
alyzed by BLI and RFP expression measurements of living animals and
isolated lungs (Fig. 7a and b). However, no BLI expressing cells were de-
tectable in mice injected with RIOK1 deﬁcient cells. Analysis of the co-
expressed RFP conﬁrmed colony formation in the lungs of mice inocu-
lated with NCI-H1299 NS but not of induced RIOK1 knockdown cells
(Fig. 7b).
Histological analysis of the lungs conﬁrmed that those cells forming
the metastatic spots highly expressed RIOK1 (Fig. 7c). Furthermore, as
this antibody recognizes an epitope only present in human RIOK1, it
can be also used to distinguish human tumor cells frommurine stroma.
Scoring of the isolated lungs of all in vivo experiments demonstrated
that, upon s.c. injection, NCI-H1299 NS control cells preferentially
formed metastases appearing as nodules of tumor cells (score 2; 10–
20 cells), whereas shRIOK1 cells formed metastases consisting of single
or few cells (score 1) (Fig. 7d, left quantiﬁcation). For i.v. injection, NCI-
H1299 shRIOK1 cells failed to colonize to the lungs in 15 out of 16 dox-
treated recipient mice, while NCI-H1299 NS control and non-induced
shRIOK1 cells formed massive colonies (score 3) in 14 out of 15 and 7
out of 8 animals, respectively (Fig. 7d, right quantiﬁcation). Taken to-
gether, these data suggest that RIOK1 depleted cells are impaired in col-
onization and implicate RIOK1 as a potential therapeutic target for
metastasis prevention.3.6. RIOK1 is Overexpressed in Human Lung- and Breast Cancer Specimens
Our preclinical ﬁndings encouraged us to analyze primary lung and
breast cancer human tissue specimens or RIOK1 expression. Indeed, in
a group of 30 lung cancer tissue specimens, we detected higher levels
of RIOK1 expression in the subtypes of squamous cell carcinoma (SCC)
(N=15), compared to a heterogeneous expression observed in the ad-
enocarcinoma subtypes (N= 15) (Fig. 8a and b).
Next, we scored RIOK1 expression in a collective of 22 breast carci-
noma samples (WHO reclassiﬁed in Table S3) with matched non-
neoplastic tissue. Expression of different histological subtypes was het-
erogeneous (Fig. 8c), whereas RIOK1 was expressed in a comparable
ratio between non-neoplastic and tumor tissue (Fig. 8d), which is in ac-
cordance to our initial in silico analysis (Fig. 1a). When analyzing RIOK1
expression and tumor grading independent of the histological subtypes,
we observed stronger RIOK1 expression in less differentiated grade 3
tumors (Fig. 8e). Important predictive markers for targeted therapies
in breast carcinomas are hormone receptor status and HER2 expression.
Therefore, we correlated the expression of the estrogen and progester-
one receptor with the expression of RIOK1. This analysis showed an in-
verse correlation between hormone receptor status and RIOK1
expression (Fig. 8f), while the proportion of RIOK1 high and lowFig. 6. RIOK1 knockdown impairs NF-κB signaling. (a) NCI-H1299 and MDA-MB-231 NF-κB lu
mean ± SEM with * for p b 0.05 by two-way ANOVA (Tukey); N= 3. (b and c) Induced NCI-
reporter plasmids and IKK2 coding plasmids (empty vector (e.V.), wildtype (WT), kinase dea
by probing lysates for Flag-tagged IKK (b) and NF-κB activity was determined (c). Data is repr
way ANOVA (Tukey); N = 3. (d) Induced NCI-H1299 non-silencing (NS) or shRIOK1 (R1)
stimulation with TNFα (10 ng/ml). Cell lysates for cytosolic (C) and nuclear (N) fractions w
controls for cytosolic and nuclear fractions, respectively. Please note the panels for pP65, P65 a
abundance and consequently the signals of these proteins strongly differ between cyto- and n
(mean ± SEM, N= 3; unpaired two-tailed t-test). (e) NCI-H1299 non-silencing (NS) or shRIO
probed for phosphorylated IκBα N= 3. (f) NCI-H1299 non-silencing or shRIOK1 cells were se
or Bay 11-7082 (10 μM) for 12 days. Scale bar: 200 μm. (See also Figs. S6 and S7).expressing tumors was comparable between HER2 negative and posi-
tive tumors (Fig. 8g).
3.7. RIOK1 Knockdown Susceptibility Does Not Necessarily Correlate With
MTAP Expression
So farwe have identiﬁed RIOK1 as a critical contributing factor to on-
cogenic RAS signaling in three distinct cancer entities using cell lines
from lung-, triple-negative breast- and colorectal cancer (Fig. 9a). How-
ever, it is likely that RIOK1 dependence is not only mediated by the RAS
mutational status. Interestingly, three recent publications identiﬁed de-
pletion of RIOK1, or its interaction partner PRMT5, as a critical prerequi-
site for synthetic lethal constellations triggered by loss of theMTAP locus
(Kryukov et al., 2016;Marjon et al., 2016;Mavrakis et al., 2016).Marjon
et al. andMavrakis et al. established this requirement for RIOK1 expres-
sion in KRASG13D mutant HCT116 colorectal and KRASG12C mutant
MiaPaCa2 pancreatic cancer cells, respectively, although the RASmuta-
tional status was not considered in the interpretation of their data. In-
deed, Marjon et al. show that RIOK1 depletion, using shRNA
constructs distinct from ours, also reduces colony growth of HCT116
cells by 40%, which is further reduced to 20% in the isogenic
MTAP−/− line. These data led to a model in which MTAP deﬁciency
leads to the accumulation of its substrate methylthioadenosine, which
represses the PRMT5/RIOK1 complex and pro-proliferative and biosyn-
thetic pathways that are positively regulated by PRMT5 (Marjon et al.,
2016). Consequently, we analyzed the MTAP status for our cell lines
(Fig. 9b). Interestingly, NCI-H1299 cells express MTAP, whereas MDA-
MB-231 do not (Fig. 9b and c). This ﬁnding correlates well with the ob-
served effects of RIOK1 depletion in these cells as MDA-MB-231
responded with an even stronger growth arrest as compared to the
NCI-H1299 cells. Furthermore, we observed MTAP expression in all an-
alyzed colorectal cancer cell lines, which could explain the less severe
effects observed in SW480, HCT116 and RKO cells upon RIOK1 knock-
down. In our two epithelial cell lines Caco-2 (MTAP proﬁcient) and
MCF-10A (MTAP deﬁcient), the effects of the RIOK1 knockdown corre-
lated again with the MTAP status. Whereas Caco-2 cells were not sus-
ceptible to RIOK1 knockdown, MCF-10A cells responded partially to
the knockdown in conventional culture but not in the more physiolog-
ical setting of 3D matrix culture. Finally, the CML cell line K562 (MTAP
deﬁcient) did not respond to RIOK1 knockdown. Thus, our data identify
RIOK1 as a potential therapeutic target in the context of RASmutations,
in particular but not exclusively in the context ofMTAP deﬁciency. Fur-
ther studieswill address thequestionwhetherMTAP (or PRMT5)deple-
tion in combination with RIOK1 deﬁciency (and oncogenic RAS
signaling) further reduces cellular ﬁtness.
4. Discussion
In this study, we identiﬁed the under-researched atypical kinase
RIOK1 as a critical contributor to the transformed phenotypes of RAS-
driven cell lines from lung, triple-negative breast and colorectal cancer.
In contrast, the growth of cell lines lacking RASmutations, such as theciferase reporter assay measured after 48 h normalized to NS dox; data is represented as
H1299 non-silencing (NS) or shRIOK1 (R1) cells were transfected with NF-κB luciferase
d (KD) or constitutive active (CA)) and lyzed after 48 h. Expression IKK2 was conﬁrmed
esented by mean ± SEM with *** for p b 0.001; ** for p b 0.01 and * for p b 0.05 by two-
cells were treated with Bay 11-7082 (10 μM) or DMSO for 1 h followed by a 15 min
ere analyzed with the indicated antibodies. 14-3-3 and Lamin B were used as loading
nd RIOK1 are composed of two exposures from the same gels. This was necessary as the
ucleoplasm. Quantiﬁcation of Western blot analysis shown in d and e is depicted below.
K1 (R1) cells were stimulated with TNFα (10 ng/ml) and cytosolic lysate fractions were
eded in 2% Matrigel and allowed to grow for 3 days before they were treated with DMSO
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line or K562 cells, driven by the potent Bcr-Abl oncoprotein, were not or
only partially affected by RIOK1 knockdown. In spontaneously immor-
talized MCF-10A mammary epithelial cells with or without ectopicKRASG12V expression, knockdown of RIOK1 partially reverted invasive
growth in 3D culture. Thus, our data demonstrating a requirement for
RIOK1 in the proliferation and invasion of carcinoma cells signiﬁcantly
extend the ﬁndings by Luo et al., who ﬁrst observed RIOK1 as a hit in a
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colorectal cancer cells (Luo et al., 2009). Based on its enzymatic charac-
ter, Luo et al. already suggested that further validation efforts will be re-
quired to assess the addiction of RASmutant cells to these genes and to
evaluate their utility as drug targets in cancer cells (Luo et al., 2009).
Further validation of RIOK1 was not conducted in this study. Since
then, however, the critical role of RIOK1 in RASmutant cells has been,
in addition to the data presented in our study, further supported by
the following screens. While our paper was under revision, Kiessling
et al. published a CRISPR/Cas9 screen in cell lines driven by either mu-
tant EGFR or NRAS (Kiessling et al., 2016). Interestingly, only the growth
of the latter was affected by RIOK1 knock-out. In that regard, we used
cBioPortal to investigate whether RIOK1 overexpression co-occurs
with HRAS or KRAS alterations in breast and lung cancer. Although this
program identiﬁed a co-occurrence for some constellations in breast
cancer (Fig. S10), we suggest that this aspect needs to be validated in fu-
ture studies that not only include the genetic alterations of RAS genes
but also of their modiﬁers such as RAS inactivating GTPase activating
proteins that are often lost in breast cancer by (epi)genomic events
(McLaughlin et al., 2013; Olsen et al., 2017).
Likewise, data in the Achilles project database demonstrate that the
“essentiality” for RIOK1 expression differs between the various cell lines
and that many RASmutant cell lines are more affected in this indepen-
dent CRISPR/Cas9 screen (Fig. S11) (https://portals.broadinstitute.org/
achilles). Thus, both CRISPR/Cas9 based data sets further support our
concept with an shRNA independent approach that RAS-driven tumor
cells are particularly reliant on RIOK1 expression. Moreover, these
data sets and our study suggest that RIOK1 depletion is not generally
toxic to cells, but might represent an Achilles heel speciﬁcally for RAS-
driven cancers. Indeed, knockdown studies on this highly conserved
atypical kinase in C. elegans show thatworms reach adulthood, although
they display defects in their reproductive system (Mendes et al., 2015;
Weinberg et al., 2014). Still, as the effects of RIOK1 deﬁciency in mam-
mals remain unknown so far, these data suggest that many cell types
do not rely on full RIOK1 expression or activity for survival or
differentiation.
So far, RIO kinases have been mostly studied in yeast, but the few
studies addressing their function in mammalian cells identiﬁed an im-
portant role of all three family members in ribosomal biogenesis
(Baumas et al., 2012; Ferreira-Cerca et al., 2014; Ferreira-Cerca et al.,
2012; Turowski et al., 2014; Zemp & Kutay, 2007). Furthermore,
RIOK1 has been implicated in cell cycle progression of the yeast
Saccharomyces cerevisiae and to promote either S-phase or G2/M transi-
tion (Angermayr et al., 2002). By our expression analysis of cell cycle
regulators in NCI-H1299 cells, we provide conﬁrmation that RIOK1 crit-
ically contributes to proliferation in mammalian cells as well. This anal-
ysis also indicates an arrest or signiﬁcant delay at the G2/M checkpoint.
Importantly, the strong requirement for RIOK1 for proliferation was
only visible in RASmutant cell lines, which identiﬁes RIOK1 as potential
vulnerability of RAS-driven tumors. As we could not observe a clear ef-
fect of RIOK1 depletion on classical RAS-controlled signaling events,
such as MEK-ERK (data not shown) or AKT phosphorylation (Figs. 5e,
S4 and S5), we posit that RIOK1 does not directly interact with RAS
proximal effectors such as Raf or PI3K. Instead we suggest that RIOK1
rather engages in a functional relationship with constitutively active
RAS in nematodes and mammalian cells.
In the present study, we also provide insights into the hardly charac-
terized RIOK1 interactome in cancer cells (Fig. 5c and Table S1). Using
co-immunoprecipitation, we conﬁrmed the well-described interactionFig. 7. RIOK1 enables lung colonization. (a) Luciferase expressingNCI-H1299 non-silencing and
98 days. (b) Ex vivo ﬂuorescence imaging of isolated lungs on day 100. N=2. Doxycycline (2 m
(H&E) and immunohistochemical (RIOK1) staining of the isolated lungs from this experiment a
bar upper panel: 200 μm. Scale bar middle and lower panel: 20 μm. (d) Upon s.c. injection (l
shRIOK1 cells formed smaller colonies consisting of single cells (score 1). In the case of i.v. in
NCI-H1299 NS and non-induced shRIOK1 cells massively inﬁltrated the lungs of recipient mic
shRIOK1 no dox and N= 16 for shRIOK1 dox for i.v. injection; Chi-square test. (See also Figs. Sof PRMT5 with RIOK1 (Guderian et al., 2011), thereby validating our
approach (Fig. S12). Furthermore, we observed a protein-protein inter-
action of wildtype and catalytically inactive RIOK1 not only with the
well-established PRMT5 interaction partner but also with itself and
RIOK3, suggesting the formation of homo- and hetero-dimers as already
reported by Kiburu and LaRonde-LeBlanc (Kiburu & LaRonde-LeBlanc,
2012). Given the fact that many kinases are activated by dimerization
(Beenstock et al., 2016; Röring et al., 2012), one can speculate that
homo- and/or hetero-dimerization of RIO kinases represents a key
step in regulating their activity or expression levels.
By studying the effects of RIOK1 depletion on the (phospho-)prote-
ome, we also provide evidence that the three RIO proteins, despite hav-
ing non-redundant functions, cross-regulate each other. Interestingly,
depletion of RIOK1 was associated with a decrease in RIOK3 levels and
an increased expression and an electrophoretic mobility shift of
RIOK2. A possible explanation for these observations might be the se-
quential binding of RIO kinases to the pre-40S ribosomal subunit. As
RIOK2 ﬁrst dissociates from the pre-40S subunit before or after binding
of RIOK1, loss of RIOK1 could block the dissociation of RIOK2 accompa-
nied with accumulation of pre-40S particles (Widmann et al., 2012).
RIOK3 is reported to bind late to the pre-40S particle most likely after
binding of RIOK1 (Baumas et al., 2012). Therefore, loss of RIOK1
would prevent RIOK3 binding to the pre-40S subunit and could lead
to degradation of RIOK3. Our data invite for further studies addressing
the stoichiometry and post-translational modiﬁcation patterns of all
three RIO kinases.
A striking ﬁnding of our study is that RIOK1 is required for the inva-
sive properties of NCI-H1299 and MDA-MB-231 cells in 3D culture and
in vivo. There are two potential, not mutually exclusive mechanisms
explaining the requirement for RIOK1 for this phenotype. Firstly, given
recent ﬁndings that local mRNA translation represents a key regulatory
event in the formation of protrusions ofMDA-MB-231 cells (Mardakheh
et al., 2015) and that RIOK1/2 are involved in the export and assembly of
40S ribosomal subunits into the cytoplasm (Kressler et al., 2010), it is
conceivable that effector proteins critical for invasion are insufﬁciently
produced in the cellular periphery. Secondly, the loss of invasive growth
could be explained by our ﬁnding that RIOK1 depletion downregulates
tonic NF-κB activity and several proteins linked to NF-κB activation
and effector functions (Fig. 6 and Tables S1 and S2). The NF-κB pathway
is activated upon several stimuli like inﬂammation and oncogenic sig-
nals, including those trigged by mutant RAS (Finco et al., 1997; Karin,
2006). In this study, we showed that RIOK1 acts in parallel to IKK com-
plexes as its depletion inhibits NF-κB signaling by preventing IκBα
phosphorylation and degradation and, as a consequence, translocation
of RelA (P65) to the nucleus. Moreover, pharmacological NF-κB path-
way inhibition at the level of IKK activation resulted in a very similar
2D and 3D growth phenotype as observed for RIOK1 knockdown. Fur-
ther evidence for this hypothesis is provided by the reduced expression
of the IKK substrate MTDH upon RIOK1 depletion. Although MTDH has
been linked to metastases in a variety of tumor entities (Shi & Wang,
2015), the exact underlying molecular mechanisms remain elusive.
However, several reports implicate MTDH as an activator and also as
an NF-κB target gene (Emdad et al., 2006; Krishnan et al., 2015). Conse-
quently it is conceivable that RIOK1 and MTDH depletion will quench
tonic NF-κB signaling triggered by oncogenic RAS. This hypothesis is fur-
ther strengthened by our preliminary data showing the reduction of
several NF-κB regulated cytokines in our cell line models (data not
shown) of which several have been also linked to cellularmigration. Fu-
ture studies will decipher the exact role of RIOK1 in NF-κB signaling andshRIOK1 cells were injected i.v. inmice and tumor growthwas followed using BLI for up to
g/ml) was administered constantly via the drinking water. (c) Representative histological
nd from s.c. injections (Figs. S8 and S9). Arrows point out RIOK1 positive tumor cells. Scale
eft), NCI-H1299 NS cells preferentially formed nodules of tumor cells (score 2), whereas
jection (right), induced NCI-H1299 shRIOK1 failed to form colonies (score 0), whereas
e (score 3). N= 7 for NS and N= 8 for shRIOK1 for s.c. injections. N= 15 for NS, N= 8
8 and S9).
Fig. 8. RIOK1protein expression in human lung andbreast carcinomas. (a) Representative lung adenocarcinomas (AC) and lung squamous cell carcinomas (SCC). RIOK1protein expression
was scored as follows: score 0 (no expression), score 1 (low expression) and score 2 (high expression). (b)Quantiﬁcation of immunohistochemical evaluation according to the histological
subtypes; N= 15 per group. (c) Representative histological (H&E) and immunohistochemical (RIOK1) staining of the lobular or the NST (no special type) subtype. (d) Comparison of
RIOK1 protein expression in normal breast epithelium and breast carcinomas. N= 22 tumor and normal matched pairs. (e) RIOK1 protein expression in breast carcinomas is linked to
histologic grading. (f and g) RIOK1 expression in breast carcinomas is inversely correlated to estrogen (ER) and progesterone (PR) receptor expression, but is not associated with HER2
expression. All images were taken with 20× magniﬁcation. AC Adenocarcinoma, SCC squamous cell carcinoma. Data in b, d–g are represented as % of analyzed cases and statistically
analyzed by Chi-square test.
94 F. Weinberg et al. / EBioMedicine 20 (2017) 79–97of downstreameffectors bywhich RIOK1 promotes the formation of cel-
lular protrusions and metastases. However, we do not rule out that the
profound effects of RIOK1 depletion on invasiveness in vitro and in vivo
are of pleiotropic nature.Regardless of the precise molecular mechanisms underlying the
protrusion and metastasis impairing effect of RIOK1 depletion, our
data already identify RIOK1 as a potential target for tumor therapy,
as Marjon et al. (2016) have also recently suggested for MTAP
Fig. 9. Heatmap of cellular behavior upon RIOK1 knockdown and MTAP status analysis. (a) Scoring determined based on densitometry measurements as follows: strongly decreased:
reduction in expression ≥ 40%; decreased: reduction in expression ≥ 20%; increased: augmented expression ≥ 50%; n.d. not determined. (b) Western blot analysis of MTAP expression
in different cell lines of colon-, breast- and und lung cancer (N= 1). (c) RIOK1 knockdown does not inﬂuence MTAP expression in NCI-H1299 and MB-MB-231 cells (N= 1).
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as such, potentially druggable by small-molecule compounds. This
makes them better suited than other synthetic lethal targets in RAS
signaling networks such as transcription factors (Cox et al., 2014;
Downward, 2015). Indeed, speciﬁc inhibitors are being developed
and have already been shown to effectively compete with ATP
and to block auto-phosphorylation activity in vitro (Kiburu &
LaRonde-LeBlanc, 2012; Mielecki et al., 2013). However, they still
need to be tested especially in the context of cancer cell growth
in vitro and in vivo. Nevertheless, RIOK1 knockdown does neither im-
pair the proliferation of K562 and Caco-2 cells nor the acinar mor-
phogenesis of MCF-10A cells, a delicate process involving various
fundamental biological processes (Debnath & Brugge, 2005). This
suggests that RIOK1 depletion will not be generally toxic and there-
fore potentially suitable for therapeutic strategies targeting RIOK1.
Indeed, Marjon et al. (2016) observed that the growth inhibitory ef-
fect of RIOK1 depletion could be rescued in both MTAP pro- and de-
ﬁcient HCT116 lines by complementation with wildtype but not with
catalytically inactive RIOK1. This ﬁnding identiﬁes the enzymatic ac-
tivity of this atypical kinase as a potential point for therapeutic inter-
vention. According to our data, such an approach would create
vulnerability for RAS-transformed cells, while having little or limited
effects on healthy cells. Together with our observation that RIOK1
promotes lung colonization in mice and the differential RIOK1 ex-
pression in human tumor tissue specimens, our data invite for fur-
ther studies addressing RIOK1 in cancer, its prognostic signiﬁcance
and suitability as a drug target.
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